Coronavirus bottleneck leaves 2m waiting for cancer care

2.1 million people are waiting for breast, bowel or cervical screening

Read on PharmaTimes

Lynparza backed by CHMP for BRCA-mutated pancreatic cancer

Lynparza is the only PARP inhibitor to show patient benefit in a Phase III trial in this setting, says AZ

Read on PharmaTimes

UK study highlights potential of genetic screening for prostate cancer

Genetic ‘barcoding’ in GP surgeries can identify men at higher risk of prostate cancer, researchers claim

Read on PharmaTimes

New centre to tackle impact of ethnicity and race on health

The NHS Race and Health Observatory will be hosted by the NHS Confederation

Read on PharmaTimes

Pfizer's Ibrance 'unlikely' to hit key early breast cancer goal

The trial is unlikely to show a statistically significant improvement in invasive disease-free survival

Read on PharmaTimes

1 2 3

Top of page

Industry News

2.1 million people are waiting for breast, bowel or cervical screening.
Read More >

More Stories

News

Recent launch of several new categories of compound which include the spirocyclic β-Lactams designed...
Read More >

More Stories

Latest Tweets

Follow Us